Inflammation

Symptoms of dry eye disease were more closely related to sleep disturbances than exam findings, although inflammation and meibum quality were linked to subjective sleep quality, according to a study in BMJ Open Ophthalmology.

An experimental drug that inhibits aldosterone production reduced albuminuria in patients with chronic kidney disease, according to phase 2 study results published in The Lancet.

The Stockholm3 multivariable blood test demonstrated superior specificity of prostate cancer detection across a diverse population compared with PSA screening, according to findings presented at ASCO Genitourinary Cancers Symposium.

Inflammasome Therapeutics announced that the first patient has been dosed in its phase 1 study of K8, a novel dual inflammasome inhibitor for treatment of diabetic macular edema.

Eyenovia has announced the reacquisition of development and commercialization rights to MicroPine, an investigational 8 µL ophthalmic atropine spray being evaluated for pediatric progressive myopia.

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.

Oculis has completed the first patient visit in its phase 3 OPTIMIZE-2 trial of OCS-01, the company’s preservative-free, once-daily topical formulation of dexamethasone for treating pain and inflammation after cataract surgery.

According to published results, use of diosmin after total knee arthroplasty was associated with reduced lower extremity swelling and reduced pain during motion with no increase in short-term complications.

Oculis has announced the first patient first visit in the second stage of its phase 3 DIAMOND-1 trial evaluating OCS-01, the company’s high-concentration formulation of dexamethasone for treatment of diabetic macular edema.